Table 1. Summary of CML patients with t(4;9;22) in previous reports
Case | Translocations | Breakpoint | Age (years) | Sex | Phase at diagnosis | WBC | Treatment | Reference |
|---|---|---|---|---|---|---|---|---|
1 | t(4;9;22)(q28;q34;q11) | 4q28 | 17 | F | CP | – | – | [6] |
2 | t(4;9;22)(p15;q34;q11) | 4p15 | 58 | M | CP | – | – | [6] |
3 | t(4;9;22)(p16;q34;q11) | 4p16 | 12 | M | BC | – | – | [8] |
4 | t(4;9;22)(p16;q34;q11) | 4p16 | 78 | M | CP | 236× \({10}^{9}\)/l | HU | [9] |
5 | t(4;9;22)(p16;q34;q11) | 4p16 | 42 | M | CP | – | – | [10] |
6 | t(4;9;22)(p16;q34;q11) | 4p16 | 59 | M | CP | 300× \({10}^{9}\)/l | HU | [11] |
7 | t(4;9;22)(p16;q34;q11) | 4p16 | – | F | – | – | – | [12] |
8 | t(4;9;22)(p14;q34;q11) | 4p14 | – | M | – | – | – | [12] |
9 | t(4;9;22)(q25;q34;q11) | 4q25 | 42 | M | AP | 72.8× \({10}^{9}\)/l | IFN-α (9 months) | [13] |
10 | t(4;9;22)(q25;q34;q11) | 4q25 | – | – | CP | – | HU, chemotherapy | [13] |
11 | t(4;9;22)(p16;q34;q11) | 4p16 | – | – | – | – | – | [14] |
12 | t(4;9;22)(p16;q34;q11) | 4p16 | – | – | – | – | – | [14] |
13 | t(4;9;22)(q12;q34;q11) | 4q12 | 44 | M | CP | – | BMT | [15] |
14 | t(4;9;22)(q21;q34;q11.9) | 4q21 | 40 | M | CP | 89.3× \({10}^{9}\)/l | TKIs | Present case |